Pharma: Page 61
-
Courtesy of Regeneron Pharmaceuticals
Regeneron and Sanofi speed Kevzara into coronavirus trials
Positive signs from a Chinese test of Roche's Actemra support the companies' decision to start studying their anti-inflammatory drug against COVID-19.
By Jonathan Gardner • March 16, 2020 -
Courtesy of Eli Lilly
With AbCellera deal, Lilly becomes latest pharma to start coronavirus program
Lilly hopes to begin human testing of a therapeutic antibody within four months, the company's top scientist said.
By Ned Pagliarulo • March 13, 2020 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
AstraZeneca and Merck's string of Lynparza successes ends in ovarian cancer
Results from a Phase 3 combination study in the tumor type read out negative, marking a rare miss for the pharmas' fast-growing cancer drug.
By Jonathan Gardner • March 12, 2020 -
Shutterstock: digitally enhanced by ZS.
Sponsored by ZSThe future of data in pharma
The world is becoming more and more data dependent while slow, tectonic shifts are under way across healthcare.
March 11, 2020 -
Yujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration
Coronavirus spread prompts FDA to postpone nearly all overseas inspections
The agency's decision was based on U.S. government travel restrictions, but it said "alternative tools and methods" will help it maintain oversight.
By Jonathan Gardner • March 10, 2020 -
Acceleron shelves drug after disappointing readout
Despite hitting the main goal of a mid-stage neuromuscular study, Acceleron isn't convinced its drug offers meaningful improvement to muscle function or quality of life.
By Jacob Bell • March 10, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from https://www.flickr.com/photos/nihgov/49565662436/in/album-72157713108522106/.
Tracking biopharma's response to the new coronavirus
The ongoing outbreak is a huge test for the biopharmaceutical industry and its ability to supply, develop, and test new drugs without disruption. Keep up with all of BioPharma Dive's coverage here.
By Jacob Bell • Updated July 7, 2020 -
Courtesy of Eli Lilly
As US coronavirus cases mount, top drugmakers tell employees to work from home
Eli Lilly and Takeda are asking thousands of their U.S.-based employees to practice "social distancing," while Biogen tries to contain an outbreak among staff who attended a Boston meeting earlier this month.
By Ned Pagliarulo • March 9, 2020 -
Jacob Bell/BioPharma Dive
AstraZeneca immunotherapy combination falls short in bladder cancer trial
Results from a Phase 3 bladder cancer study combining two checkpoint inhibitors failed to show a survival benefit, raising questions about other trials.
By Jonathan Gardner • March 6, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49565158908/in/album-72157713108522106/.
Takeda starts work on treatment for coronavirus illness
The plan is to take blood proteins of patients recovering from the novel virus and turn them into an immune-boosting therapy that mitigates or prevents illness in others.
By Jacob Bell • March 4, 2020 -
Federal prosecutors make another claim against Mallinckrodt over Acthar prices
A quirk in the FDA approval for the multi-use drug allowed first Questcor and then Mallinckrodt to understate rebates owed to Medicaid, the lawsuit claims.
By Jonathan Gardner • March 4, 2020 -
High prices fuel pharma profits. New research provides more context
Drugmakers often enjoy significantly wider net income margins than large companies in other industries, and those profits have come amid steady list — and net — price hikes for hundreds of medicines.
By Ned Pagliarulo • March 3, 2020 -
New estimate puts cost to develop a new drug at $1B, adding to long-running debate
Pharma companies spend $300 million to $400 million bringing a new medicine to market, but per-product R&D costs are much higher after accounting for the many drugs that fail in testing.
By Jonathan Gardner • March 3, 2020 -
Courtesy of Sanofi
Sanofi wins US approval for myeloma drug key to its cancer ambitions
Sarclisa is the first cancer drug wholly owned by Sanofi to win an FDA OK in a decade — a milestone in the pharma's bid to play a larger role in oncology.
By Ned Pagliarulo • March 2, 2020 -
Getty / Edited by BioPharma Dive
Sangamo sees vindication in Biogen gene-editing deal
Delivering products nearly ready for clinical testing has sparked greater dealmaking interest from big pharma, Sangamo's CEO told BioPharma Dive.
By Jonathan Gardner • Feb. 28, 2020 -
Elizabeth Regan/BioPharma Dive
Takeda's small celiac disease bet turns into acquisition
Phase 1 data triggered a takeout of PvP Biologics worth up to $330 million, giving Takeda access to a drug invented by a University of Washington team.
By Jonathan Gardner • Feb. 26, 2020 -
Amid coronavirus fears, a generics giant pledges price stability
For the roughly two dozen drugs Sandoz deemed essential, it will refrain from list price increases, rebate decreases or other actions that would increase commercial drug costs for healthcare systems.
By Jacob Bell • Feb. 26, 2020 -
Mallinckrodt offers $1.6B in deal to settle opioid claims
Under the proposed settlement, which has the support of state governments, Mallinckrodt's generics unit would file for bankruptcy protection.
By Jonathan Gardner • Feb. 25, 2020 -
As shortages draw spotlight, Sanofi to spin out drug ingredient business
The new company will launch with significant size, employing 3,100 and drawing from a network of six factories across Europe.
By Ned Pagliarulo • Feb. 24, 2020 -
Chinese biotech enlists GSK in coronavirus vaccine effort
Clover Biopharmaceuticals will pair GSK's adjuvant technology with a protein-based vaccine it recently began developing in response to the viral outbreak.
By Ned Pagliarulo • Feb. 24, 2020 -
Esperion adds more competition to cholesterol drug market
Following an FDA approval Friday, Esperion intends to sell bempedoic acid under the brand name Nexletol for a price of about $10 per day.
By Jacob Bell • Feb. 21, 2020 -
Teva's neuroscience drug falls short at the finish line
Austedo, a main growth driver for Teva, failed two late-stage studies that were supposed to get the drug approved as a treatment for tics in young patients with Tourette's.
By Jacob Bell • Feb. 20, 2020 -
Sanofi starts work on coronavirus vaccine, bringing scale to global research effort
The French drugmaker joins J&J as the second large pharmaceutical company to begin development of a vaccine against the virus that's spread quickly across China.
By Ned Pagliarulo • Feb. 18, 2020 -
Coronavirus weighs on AstraZeneca's China expansion
The British drugmaker cautioned the disease outbreak could impact its sales in the country, where restrictions on travel and commerce have been imposed to contain the virus' spread.
By Jonathan Gardner • Feb. 14, 2020 -
Bristol-Myers finds FDA receptive to speedy review of key cell therapy
The regulator agreed to decide by mid-August on approval of Bristol-Myers' CAR-T treatment liso-cel, one of three drugs prominently featured in the pharma's buyout of Celgene last year.
By Ned Pagliarulo • Feb. 13, 2020
Previous
